ArticleClinical and translational radiation oncology2026
Impact of excluding internal mammary node coverage on musculoskeletal dosimetry in breast radiotherapy.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Volume ratio factor: a novel CT-derived biomarker for pre-planning ipsilateral lung dose risk stratification in breast cancer radiotherapy.Quantitative imaging in medicine and surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Breast cancer radiotherapy (RT) can lead to shoulder complications including weakness, restricted motion, and discomfort, affecting up to 40% of patients. The necessity to include the internal mammary nodes (IMNs) during breast and nodal irradiation for every patient remains under discussion, particularly for early-stage breast cancers. The dosimetric effect on nearby musculoskeletal (MSK) structures when targeting the IMNs remains to be completely understood; hence the focus of this current study. Methods: This retrospective study included breast cancer patients who underwent lumpectomy and nodal sampling followed by adjuvant hypofractionated whole breast and regional nodal RT (4005 cGy in 15 fractions) who were treated between January 1, 2022, and November 30, 2023 at a single institution. MSK structures such as the bones (ribs, scapula), muscles (pectoralis, rhomboids), and joints (glenohumeral, acromioclavicular) were retrospectively contoured on the CT simulation images. Two RT plans (one with and one without IMN coverage) were created, and dosimetric parameters including mean (Dmean), near maximum (D2), near minimum (D98) and volumes received 15, 20 and 40 Gy (V15, V20, V40) were compared. Standardized mean difference between the plans was calculated for each dosimetric parameter, and Wilxocon's signed-rank test was used for comparison. Univariable linear regression analysis was used to identify patient and tumor factors that were associated with more significant dosimetric differences. Results: A total of 30 breast cancer patients with a median age of 63 (range 30-82 years) were selected for analysis. The location of tumours included 15 (50 %) in the right breast, and 15 (50 %) in the left breast; with 10 (33 %) centrally, 10 (33 %) medially, and 10 (33 %) were laterally-located within the breast. The pathologic T stage included 6 (20 %) T0/Tis, 11 (37 %) T1, and 13 (43 %) T2. Seven patients (23 %) were N0, 19 (63 %) were N1, and 4 (13 %) were N2a. Nine patients received adjuvant chemotherapy, 11 neoadjuvant chemotherapy, and 10 patients received no chemotherapy.The exclusion of IMN coverage led to significantly decreased Dmean for muscle groups in the posterior, posterolateral, lateral, anterior and antero-lateral-posterior regions. Specifically, the largest absolute reductions included teres major (Dmean 340 cGy), subscapularis (320 cGy), serratus anterior (241 cGy), latissimus dorsi (232 cGy), chestwall (209 cGy), and the pectoralis minor (37 cGy) muscles. Significant differences were also observed for V40 and V15 of pectoralis minor (V40 of 12 %), pectoralis major (V40 of 10 %), and for both subscapularis and teres major (V15 of 8 %) muscles.Patient factors that were associated with greater dosimetric differences included younger age, larger breast size, larger tumor cavity, and non-central tumor locations. Conclusion: This retrospective
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.